Literature DB >> 11414556

A model for a proportional treatment effect on disease progression.

T Greene1.   

Abstract

Treatments intended to slow the progression of chronic diseases are often hypothesized to reduce the rate of further injury to a biological system without improving the current level of functioning. In this situation, the treatment effect may be negligible for patients whose disease would have been stable without the treatment but would be expected to be an increasing function of the progression rate in patients with worsening disease. This article considers a variation of the Laird Ware mixed effects model in which the effect of the treatment on the slope of a longitudinal outcome is assumed to be proportional to the progression rate for patients with progressive disease. Inference based on maximum likelihood and a generalized estimating equations procedure is considered. Under the proportional effect assumption, the precision of the estimated treatment effect can be increased by incorporating the functional relationship between the model parameters and the variance of the outcome variable, particularly when the magnitude of the mean slope of the outcome is small compared with the standard deviation of the slopes. An example from a study of chronic renal disease is used to illustrate insights provided by the proportional effect model that may be overlooked with models assuming additive treatment effects.

Entities:  

Mesh:

Year:  2001        PMID: 11414556     DOI: 10.1111/j.0006-341x.2001.00354.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  5 in total

1.  Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.

Authors:  Tom Greene; Jian Ying; Edward F Vonesh; Hocine Tighiouart; Andrew S Levey; Josef Coresh; Jennifer S Herrick; Enyu Imai; Tazeen H Jafar; Bart D Maes; Ronald D Perrone; Lucia Del Vecchio; Jack F M Wetzels; Hiddo J L Heerspink; Lesley A Inker
Journal:  J Am Soc Nephrol       Date:  2019-07-10       Impact factor: 10.121

2.  Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Authors:  Christoph Wanner; Hiddo J L Heerspink; Bernard Zinman; Silvio E Inzucchi; Audrey Koitka-Weber; Michaela Mattheus; Stefan Hantel; Hans-Juergen Woerle; Uli C Broedl; Maximilian von Eynatten; Per-Henrik Groop
Journal:  J Am Soc Nephrol       Date:  2018-10-12       Impact factor: 10.121

3.  Arteriovenous fistula creation may slow estimated glomerular filtration rate trajectory.

Authors:  Thomas A Golper; Phillip Matthew Hartle; Aihua Bian
Journal:  Nephrol Dial Transplant       Date:  2015-04-16       Impact factor: 5.992

4.  Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).

Authors:  Jennifer J Gassman; Tom Greene; Jackson T Wright; Lawrence Agodoa; George Bakris; Gerald J Beck; Janice Douglas; Ken Jamerson; Julia Lewis; Michael Kutner; Otelio S Randall; Shin-Ru Wang
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

Review 5.  Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs.

Authors:  Hyo Jin Kim; Sang Soo Kim; Sang Heon Song
Journal:  Korean J Intern Med       Date:  2022-04-04       Impact factor: 3.165

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.